Phase II evaluation of bleomycin. A Sout
โ
Charles D. Haas; Charles A. Coltman Jr.; Jeffrey A. Gottlieb; Arthur Haut; James
๐
Article
๐
1976
๐
John Wiley and Sons
๐
English
โ 369 KB
๐ 1 views
Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice-weekly doses of 10 mg/mz was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and